COMPARE · Data as of August 21, 2026
HALO vs INSM
Verdict: Side-by-side breakdown using the Bull Rankings model. HALO scored 79.5, INSM scored 38.6 — HALO leads.
Compare another set
HALO
Halozyme Therapeutics, Inc.
79.5
$108.17 · $12.3B
fundamentals as of
Score gap
40.9
HALO leads
INSM
Insmed Incorporated
38.6
$125.77 · $27.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthINSM+185.8%
- Highest qualityHALO96 / 100
- Largest discount to fair valueHALO-38%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
HALO
stronger →← stronger
INSM
96
Qualityreturns · margins · balance sheet
11
97
Growthrevenue & earnings expansion
98
54
Valuevaluation vs sector peers
55
INSM is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
HALO
INSM
$806mC+
FCF
-$808mF
+41.2%A
Rev
+185.8%A
—
D/E
0.98C
31.7xB
P/E
—
1.47B
PEG
1.09B+
—
P/S
24.1xD
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
HALO
INSM
38% below
Price vs fair valuelower is cheaper
—
~1%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
+29%
1-yr DCF upside
—
+63%
5-yr DCF upside
—
+129%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
HALO
Why this score
- Buying back stock
- Durable high returns
INSM
Why this score
- Diluting shareholders
The companies
HALOHalozyme Therapeutics, Inc.
Why now
Biotechnology · market cap $12.3b. Trading near 52-week high of $108.49 — momentum setup, limited technical margin of safety. Revenue growing +41% — in hypergrowth territory. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $99.56 (implying -8% upside).
Moat
Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 195% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 32x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
INSMInsmed Incorporated
Why now
Biotechnology · market cap $27.5b. Down 41% from 52-week high of $212.75 — deep drawdown territory. Revenue growing +186% — in hypergrowth territory. 22 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $200.05 (implying +59% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$808m) — capital raises or debt issuance likely required; dilution / leverage risk. Currently unprofitable (margin -76.9%) — path to GAAP profitability is the core thesis risk. Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where HALO and INSM diverge
On the headline score the gap is 40.9 points in favor of HALO. The widest single difference is Quality, where HALO leads by 85.1 points.
- QualityHALO 95.7 · INSM 10.6HALO +85.1
- ValueHALO 54.1 · INSM 55.5level
- GrowthHALO 97.0 · INSM 97.8level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.